COPD exacerbations: targeting IL-33 as a new therapy

Affiliations

¹ Centre for Inflammation, Centenary Institute, and University of Technology Sydney, Faculty of Science, Sydney, NSW 2050, Australia; Priority Centre for Healthy Lungs, Hunter Medical Research Institute and The University of Newcastle, Newcastle, NSW, Australia.
² Woolcock Institute of Medical Research, University of Sydney and School of Life Sciences, University of Technology Sydney, Sydney, NSW, Australia.
³ Priority Centre for Healthy Lungs, Hunter Medical Research Institute and The University of Newcastle, Newcastle, NSW, Australia.
⁴ Centre for Inflammation, Centenary Institute, and University of Technology Sydney, Faculty of Science, Sydney, NSW 2050, Australia; Priority Centre for Healthy Lungs, Hunter Medical Research Institute and The University of Newcastle, Newcastle, NSW, Australia. Electronic address: chantal.donovan@uts.edu.au.

Comment

Richard Y Kim et al. Lancet Respir Med. 2021 Nov.

. 2021 Nov;9(11):1213-1214.

doi: 10.1016/S2213-2600(21)00182-X. Epub 2021 Jul 21.

¹ Centre for Inflammation, Centenary Institute, and University of Technology Sydney, Faculty of Science, Sydney, NSW 2050, Australia; Priority Centre for Healthy Lungs, Hunter Medical Research Institute and The University of Newcastle, Newcastle, NSW, Australia.
² Woolcock Institute of Medical Research, University of Sydney and School of Life Sciences, University of Technology Sydney, Sydney, NSW, Australia.
³ Priority Centre for Healthy Lungs, Hunter Medical Research Institute and The University of Newcastle, Newcastle, NSW, Australia.
⁴ Centre for Inflammation, Centenary Institute, and University of Technology Sydney, Faculty of Science, Sydney, NSW 2050, Australia; Priority Centre for Healthy Lungs, Hunter Medical Research Institute and The University of Newcastle, Newcastle, NSW, Australia. Electronic address: chantal.donovan@uts.edu.au.

No abstract available

Conflict of interest statement

We declare no competing interests.

Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.
Rabe KF, Celli BR, Wechsler ME, Abdulai RM, Luo X, Boomsma MM, Staudinger H, Horowitz JE, Baras A, Ferreira MA, Ruddy MK, Nivens MC, Amin N, Weinreich DM, Yancopoulos GD, Goulaouic H. Rabe KF, et al. Lancet Respir Med. 2021 Nov;9(11):1288-1298. doi: 10.1016/S2213-2600(21)00167-3. Epub 2021 Jul 21. Lancet Respir Med. 2021. PMID: 34302758 Clinical Trial.